SUNRAY-02

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06890598?viewType=Card&id=j3m-mc-jzqh&rank=1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center

Contact: Carissa Tipping: Carissa.Tipping@hhchealth.org